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Abstract 
Autism Spectrum Disorder (ASD) refers to a heterogenous neurological condition 
characterized by repetitive and restrictive behaviors and social communication deficits. ASD 
diagnoses are at a record high, at approximately 1 in 59 children according to the US Center 
for Disease Control. Currently, there are no available interventions that effectively treat the 
core symptoms of ASD. All pharmaceutical options address comorbid side effects of ASD 
but not core deficits and are particularly associated with negative side effects. Additionally, 
there are economic and geographic barriers that can prevent families of individuals with ASD 
from seeking or receiving effective interventions. Many of the available interventions are 
extremely costly, time-consuming, and age dependent. These factors, as well as others, have 
led to an increase in families independently utilizing complementary and alternative 
interventions. Due to the large amount of misinformation available on the Internet, families 
have become more susceptible to trying alternative forms of interventions that have not been 
scientifically proven as effective, and in some cases, are significantly detrimental. Thus, the 
need for accessible and inexpensive evidence-based nonpharmaceutical interventions is 
critical and must be addressed. Fortunately, recent groundbreaking research has discovered 
two strains of probiotics, Bacteroides fragilis and Lactobacillus reuteri, that have been 
shown to ameliorate behavioral and social deficits respectively, in validated ASD mouse 
models in a non-age-dependent manner. Probiotic intervention with a combination of these 
specific strains would effectively target both repetitive behaviors and social deficits, core 
ASD symptoms, and provide families with an accessible and inexpensive form of 
intervention. The mechanisms underlying the efficacy of these probiotics are thought to be 
associated with the gastrointestinal (GI) system and the oxytocin pathway. This study seeks 
to examine the necessity of accessible nonpharmaceutical interventions and to provide an 
effective intervention that is neither expensive or age dependent. This study also aims to 
provide greater insight into the pathways and systems in which these probiotics operate. 
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I. Introduction 
 Autism spectrum disorder (ASD) is a pervasive neurodevelopmental disorder that 
encompasses a wide range of pathology. The most recent estimate of the incidence of autism 
in America is from the Center of Disease Control and Prevention (CDC, 2018) in 2014. The 
CDC’s Autism and Developmental Disabilities Monitoring (ADDM) estimates that about 1 
in 59 children has been diagnosed with ASD. Studies in Asia, Europe, and North America 
have estimated an average prevalence of ASD as between 1%-2% (CDC, 2018). The 
estimated worldwide incidence rate is about 1% (Lai, Lombardo, & Baron-Cohen, 2014). 
ASD diagnoses are at a historic high and with such a large population of individuals, ASD 
and ASD treatments have gained greater importance.  
Additionally, the financial burden that accompanies a diagnosis of autism is 
astonishingly excessive. It is estimated that in the United States, the total costs per year for 
children with ASD falls between $11.5 billion- $60.9 billion (2011 US dollars) (CDC, 2018). 
This number includes a variety of direct and indirect costs from medical care, loss of parental 
economic productivity, and special education (CDC, 2018). On average, the average medical 
expenditures of children and adolescents with ASD exceeded those without ASD by $4,110-
$6,200 per year, approximately 4.1-6.2 times greater (CDC, 2018). In addition to medical 
expenditures, general expenditures were 8.4-9.5 times greater for children and adolescents 
with ASD, in comparison to those without (CDC, 2018). In 2005, the average annual medical 
costs for Medicaid-enrolled children with ASD were $10,709 per child, while the average 
costs for children without ASD was $1,812, approximately six times less (CDC, 2018). Early 
intensive behavioral interventions, one of the most effective interventions available, can cost 
between $40,000-$60,000 annually per child (CDC, 2018). Thus, ASD places a huge 
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economic burden on affected families and there is a dire need for more affordable treatment 
options as ASD indiscriminately affects families of all socio-economic levels. 
Before the widespread application of early intervention programs, studies showed that 
58%-78% of adults with autism had poor or very poor outcomes in terms of independent 
living, educational attainment, employment, and peer relationships (Lai, Lombardo, & 
Baron-Cohen, 2014). Only 46% of adults with autism are employed (regular, supported, or 
sheltered) (Lai, Lombardo, & Baron-Cohen, 2014). Creating an accessible and inexpensive 
non-pharmaceutical intervention that is not time-sensitive, like previous interventions that 
must be applied early in life to be effective, will allow adults with ASD to increase their 
independence and better their life outcomes. This would also decrease the large financial 
responsibility associated with the life-long care of dependent adults with ASD. 
Currently, there are no available treatment options for individuals with ASD that are 
both inexpensive and easily accessible. However, recent research and its resulting 
revolutionary evidence points to a promising new avenue of intervention; the use of 
probiotics. There are two specific probiotic strains that have been identified as having the 
potential to become a relatively accessible and affordable means of intervention for 
individuals with ASD; Bacteroides fragilis and Lactobacillus reuteri. Furthermore, evidence 
shows that intervention with these particular probiotic strains may improve the core 
symptoms of ASD, deficits in social communication and repetitive behavior, a feat that has 
not been accomplished by any of the current treatment options available to those with ASD 
(Hsiao et al., 2013; Buffington et al., 2016; Sgritta et al., 2019). 
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II. Background 
1.Autism Spectrum Disorder 
Symptoms 
The hallmark symptoms of ASD are difficulties in social communication and social 
interaction, and restricted, repetitive behavior, interests, or activities (APA, 2013). The 
cognitive abilities of people with ASD can range from gifted to severely challenged, 
representative of the wide range of symptomology and severity in ASD (CDC, 2018). About 
45% of individuals with ASD have intellectual disability and 32% experience regression 
(Lai, Lombardo, & Baron-Cohen, 2014). ASD is also associated with poor mental flexibility, 
thought to be an underlying basis of repetitive behaviors and restrictive interests (Mišić et al., 
2015). Fixations tend to involve systems that operate deterministically and repeatably 
according to salient sets of rules (Belmonte et al., 2014). Stereotyped movements and 
compulsive and repetitive behavior are common and self-injurious behavior occurs in 
approximately 30% of children with ASD (Amihaesei & Stefanachi, 2013). There are 
different severities of speech impairments; some children never fully develop speech, or are 
limited to echolalia (Belmonte et al., 2014).  Communication impairment also includes 
nonverbal signals such as gaze, facial expression, and gestures (Belmonte et al., 2014). Social 
deficits involve difficulty with processing information of other people as well as self-
referential information (Lai, Lombardo, & Baron-Cohen, 2014). Other common symptoms 
include sensory abnormalities, motor impairment, and alimentary abnormalities (Amihaesei 
& Stefanachi, 2013). In addition, comorbidity is frequent in ASD populations; more than 
70% of individuals with ASD have concurrent developmental, or psychiatric conditions (Lai, 
Lombardo, & Baron-Cohen, 2014). Commonly associated comorbidities include intellectual 
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delay, epilepsy, metabolic syndromes, ADHD, Tourette syndrome, and sleep issues 
(Amihaesei & Stefanachi, 2013). Headaches/migraines, respiratory issues, food allergies, 
physician visits, prescription medication, and rate of infections are also more common in 
children with ASD (Rodriguez & Kern, 2011). A meta-analytic study showed that the 
mortality risk of individuals with ASD is 2.8 times higher than those without, despite 
controlling for age and sex and is thought to be related to concurrent medical conditions (Lai, 
Lombardo, & Baron-Cohen, 2014). Approximately 25% of children with ASD develop 
seizures, although this is more common in girls with ASD than in boys with ASD. The 
prevalence of sleep problems including disturbed sleep, decreased sleep duration, and 
increased sleep onset delay, is higher in children with ASD than in children with intellectual 
impairment (Belmonte et al., 2014). GI disorders are also more 3.5 times more prevalent in 
children with ASD (Sharon, Sampson, Geschwind, & Mazmanian, 2016). 
The numerous symptoms and comorbidities that accompany an ASD diagnosis often 
cause some amount of impairment in independent living and sustaining social relationships. 
Although impairment can range from nearly insignificant to considerably pronounced, 
individuals with ASD face the common challenge of creating and maintaining social 
relationships and managing restrictive and repetitive behavior. These core symptoms have 
yet to be improved by any currently available interventions. 
2.Diagnostic Criteria 
 To be diagnosed with ASD, certain clinical requirements, provided in the Diagnostic 
and Statistical Manual of Mental Disorders (DSM) must be met. The most current version is 
the DSM 5, published by the American Psychiatric Association (APA, 2013). 
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 The diagnostic criteria from the DSM 5 is as follows:  
A. Persistent deficits in social communication and social interaction across multiple 
contexts, as manifested by the following, currently or by history: 
a. Deficits in social-emotional reciprocity 
b. Deficits in nonverbal communication behaviors used for social interaction 
c. Deficits in developing, maintaining, and understanding relationships 
 
B. Restricted, repetitive patterns of behavior, interests, or activities, as manifested by at 
least two of the following, currently or by history: 
a. Stereotyped or repetitive motor movements, use of objects, or speech 
b. Insistence on sameness, inflexible adherence to routines, or ritualized patterns 
of verbal or nonverbal behavior 
c. Highly restricted, fixated interests that are abnormal in intensity or focus 
d. Hyper- or hyporeactivity to sensory input or unusual interest in sensory 
aspects of the environment 
C. Symptoms must be present in early development (but may not become fully manifest 
until social demands exceed limited capacities or may be masked by learned 
strategies in later life). 
D. Symptoms cause clinically significant impairment in social, occupational, or other 
important areas of current functioning. 
E. These disturbances are not better explained by intellectual disability (intellectual 
developmental disorder) or global developmental delay. 
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Accompanying the diagnosis is an assessment of severity, from one to three, with one being 
the least severe and three being the most severe and is shown in Table 1 (APA, 2013). 
 
An ASD diagnosis now encompasses several conditions that were formerly diagnosed 
separately including: Asperger syndrome, typical autism, pervasive developmental disorder 
not otherwise specified (PDD-NOS), Rett syndrome, and child disintegrative disorder (CDD) 
which all vary in severity (CDC, 2018; Amihaesei & Stefanachi, 2013). ASD is 
approximately four times more common amongst boys than girls, although it occurs in all 
racial, ethnic, and socioeconomic groups (CDC, 2018). However, it is more common in 
Caucasian children compared to African-American or Hispanic children (Bhat, Acharya, 
Adeli, Bairy, & Adeli, 2014). 
 Early indicators of ASD include delays in verbal and nonverbal communication, 
reciprocal affective behavior, joint attention and pretend play, atypical implicit perspective 
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taking, unusually repetitive behaviors, inflexibility in visual disengagement, and extreme 
variation in temperament (Amihaesei & Stefanachi, 2013; Lai, Lombardo, & Baron-Cohen, 
2014). Studies have shown that parents tend to notice a developmental problem before their 
child’s first birthday if their child has ASD (CDC, 2018). Popular instruments used to aid in 
diagnosis include the Autism Diagnosis Interview-Revised, the Autism Diagnosis 
Observation Schedule, and the Childhood Autism Rating Scale (Amihaesei & Stefanachi, 
2013). ASD diagnoses by clinicians are considered very reliable by the age of 2, although 
most children with ASD are not diagnosed until after 4 (CDC, 2018). 
 There is a sizeable range of ages at which individuals receive their ASD diagnoses. 
The variability in age at diagnosis can affect the opportunity of individuals with ASD to 
receive early intensive behavioral intervention, currently the most effective intervention. 
Thus, there is a clear need for an intervention that remains effective at all ages. 
3.Etiology 
 The etiology of ASD is extremely complex and relatively unexplained, despite the 
substantial amount of research dedicated to this topic of interest. There have been hundreds 
of different factors implicated in the genesis of ASD, including environmental, biological, 
and genetic factors (CDC, 2018). This expansive variety of known precipitators of ASD 
parallels the extreme heterogeneity of the disorder. The critical period for developing ASD is 
thought to be before, during, and immediately after birth (CDC, 2018). 
Genetics 
There is a strong genetic component to the genesis of autism and it has been well 
researched. Over 90% of ASD incidence is estimated to be attributed to genetic factors 
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(Amihaesei & Stefanachi, 2013). Studies have shown extraordinary heterogeneity in ASD, 
predicting hundreds of rare risk genes, none accounting for more than 1% of cases 
(Peñagarikano et al., 2015). Researchers estimate that up to 1000 genes, with a high degree 
of locus heterogeneity, are also implicated in ASD (Lai, Lombardo, & Baron-Cohen, 2014). 
Many of the risk genes regulate synaptic functions of neurons that underly learning and 
plasticity (Guastella and Hickie, 2016). Having a sibling with ASD increases risk of having 
ASD; hereditary transmission in families with individuals with ASD is approximately 30% 
(CDC, 2018; Amihaesei & Stefanachi, 2013). Certain genetic or chromosomal conditions 
such as fragile X syndrome, Down’s syndrome, and tuberous sclerosis are correlated with 
increased incidence of ASD (CDC, 2018). Around 10% of the ASD population have 
comorbid genetic or chromosomal disorders (Bhat, Acharya, Adeli, Bairy, & Adeli, 2014). 
Rare de novo mutations (copy number variations [CNVs] in the form of microdeletion or 
microduplication, and nonsense, splice-site, and frame-shift mutations) have also been 
implicated in the genesis of ASD (Lai, Lombardo, & Baron-Cohen, 2014; Bhat, Acharya, 
Adeli, Bairy, & Adeli, 2014). For example, the mutation of CHD8 (chromodomain helicase 
DNA binding protein 8) gene is linked to the development of ASD and results in 
macrocephaly and wide set eyes (Bhat, Acharya, Adeli, Bairy, & Adeli, 2014). The large 
network of genes affected by de novo CNVs are primarily related to synaptic development, 
axon guidance, and neuron motility (Gilman et al., 2011; Bhat, Acharya, Adeli, Bairy, & 
Adeli, 2014). Both large-effect rare mutations and small-effect common variants contribute 
to risk of ASD (Lai, Lombardo, & Baron-Cohen, 2014). Rare mutations associated with ASD 
can occur in the form of Mendelian genetic syndromes (also called syndromic autism), 
chromosomal abnormalities, rare CNVs, and single nucleotide variants (Lai, Lombardo, & 
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Baron-Cohen, 2014). In simplex cases, when only one individual in the family has autism, de 
novo mutations are thought to be significant contributors to the genesis of ASD (Lai, 
Lombardo, & Baron-Cohen, 2014). Genome-wide association studies have identified many 
significant single nucleotide polymorphisms, but none of these have a large enough effect to 
be causal (Lai, Lombardo, & Baron-Cohen, 2014). Gene networks regarding neuronal 
function are under expressed in ASD while gene networks associated with immune function 
are overexpressed (Lai, Lombardo, & Baron-Cohen, 2014). Many of the genes implicated in 
ASD have a high degree of pleiotropy (one gene affects more than one phenotype) (Lai, 
Lombardo, & Baron-Cohen, 2014). The gender discrepancy in the incidence of ASD is in 
part explained by mutations in the X chromosome patched-related (PTCHD1) gene which 
result in a recessive phenotype in girls and a dominant phenotype in boys (Falco, 2014). This 
gene mutation has been implicated in the development of autism (Falco, 2014). Another 
contributor, duplications in the 15q11-13 loci are also associated with ASD (Wagner). Gene 
mutations can also affect the formation of cortex layers, resulting in cortical disorganization 
(Bhat, Acharya, Adeli, Bairy, & Adeli, 2014).  
Environment 
Advanced parental age, both paternal and maternal, at the time of conception is 
implicated in the development of ASD (Amihaesei & Stefanachi, 2013; CDC, 2018; Lai, 
Lombardo, & Baron-Cohen, 2014). Gestational factors, such as gestational diabetes, 
metabolic conditions, and obesity, also affect neurodevelopment and increase the likelihood 
of ASD (Amihaesei & Stefanachi, 2013; Bhat, Acharya, Adeli, Bairy, & Adeli, 2014; 
Buffington et al., 2016). Additional perinatal risk factors include: small birth weight, hypoxia 
at birth, and mercury, radiation, and diesel exhaust exposure (Amihaesei & Stefanachi, 2013; 
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Bhat, Acharya, Adeli, Bairy, & Adeli, 2014). The prescription drugs valproic acid and 
thalidomide, taken during pregnancy, also increases risk of having a child with ASD, as well 
as maternal viral infection (CDC, 2018; Bhat, Acharya, Adeli, Bairy, & Adeli, 2014; 
Belmonte et al., 2014). 
Recent evidence supports the association between ASD and extensive biological 
systems dysregulation, the most significant being the gastrointestinal environment, immune-
inflammation pathways, and nervous system (Azhari, Azizan, & Esposito, 2018; Belmonte et 
al., 2014).  
Immune System 
Ongoing neuroinflammation in various brain regions has been found in children with 
ASD (Rodriguez & Kern, 2011). This is supported by post-mortem brain examinations that 
found elevated levels of activated microglia and astrocytes and irregular, proinflammatory 
cytokine profiles (Rodriguez & Kern, 2011). Extended microglia activation increases the 
production of mediators which results in a loss of synaptic connections, underconnectivity 
and neuronal cell death (Rodriguez & Kern, 2011). Additionally, changes in major 
histocompatibility complex (MHC) expression can lead to neurodevelopmental defects as 
neurons in developing and adult brains express these proteins (Belmonte et al., 2014). 
Cerebellar Purkinje cells are a site of MHC class 1 expression and they are significantly 
reduced in number in ASD (Belmonte et al., 2014; Rodriguez & Kern, 2011) Decreased 
expression of MHC class 1 impairs the pruning of inappropriate synaptic connections, which 
could contribute to the increased brain volume of individuals with ASD at birth (Belmonte et 
al., 2014). The abnormal immune-inflammation profile of individuals with ASD contributes 
to the irregular organization and dysfunction of the nervous system. 
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Neurobiology 
 Atypical neural development at the systems level results in the atypical cognitive 
profiles found in ASD, such as impaired social cognition and perception, executive 
dysfunction, and atypical information processing (Lai, Lombardo, & Baron-Cohen, 2014). 
The brain regions involved in social perception and cognition, including the medial 
prefrontal cortex, superior temporal sulcus, temporoparietal junction, amygdala, and fusiform 
gyrus, are hypoactive in ASD (Lai, Lombardo, & Baron-Cohen, 2014). However, recent 
evidence supports the idea that ASD is characterized by atypical neural connectivity rather 
than a discrete set of abnormal brain regions (Lai, Lombardo, & Baron-Cohen, 2014). The 
brains of people with ASD are overdeveloped at birth as evidenced by increases in neuronal 
count and synapses in key cortical zones, and unbalanced functioning of the neuronal 
excitatory, versus inhibitory, networks (Amihaesei & Stefanachi, 2013). Increased brain 
volume at birth is further specified as an excessive volume of cerebrum and cerebral white 
matter with the greatest degree of enlargement in the frontal lobes and the least in the 
occipital lobes (Belmonte et al., 2014). Abnormal early neurodevelopment includes early 
postnatal brain overgrowth and subsequently stunted growth in both white and grey matter, 
disorganization of cortical layers affecting both horizontal laminar compartments and vertical 
columnar structure, and reduced functional and anatomical connectivity (Belmonte et al., 
2014, Nair et al., 2013). Aberrant organization and decreased coherence are a product of 
differences in white matter microstructure, in both white matter tracts and the superior 
temporal gyrus, in individuals with ASD (Mišić et al., 2015; Anderson et al., 2011). 
Abnormalities in synaptic and columnar structure and neuronal migration, are also found in 
the cerebral cortexes of ASD subjects (Bhat, Acharya, Adeli, Bairy, & Adeli, 2014). The 
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cortical areas that are essential to complex cognitive functions are the most affected and ASD 
also affects the temporal organization of these areas which results in impaired cognitive set 
shifting (Belmonte et al., 2014; Mišić et al., 2015). Cerebellar activation of ASD subjects 
during cognitive tasks reflects the opposite of controls (Belmonte et al., 2014). There is also 
increased cortical thinning in the frontal lobe, parietal lobe, occipital lobe, and cortex in ASD 
(Zielinski et al., 2014). The functioning of the neural network involved in social and 
emotional processing, including mirror neurons, is reduced in ASD and there are disruptions 
in cortical response to dynamic social stimuli (Amihaesei & Stefanachi, 2013; Bhat, 
Acharya, Adeli, Bairy, & Adeli, 2014).  
Functional connectivity is significantly altered in ASD subjects and is represented in 
Figure 1 (Amihaesei & Stefanachi, 2013; Rodriguez & Kern, 2011; Tyszka, Adolphs, Paul, 
& Kennedy, 2013).  
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Figure 1. The atypical functional connectivity of an autistic brain compared to a 
neurotypical brain. (Bhat, Acharya, Adeli, Bairy, & Adeli, 2014) 
The degree of connectivity abnormality is correlated with the severity of ASD 
symptomology (Rodriguez & Kern, 2011). Functional and anatomical connectivity between 
the cerebral cortex and thalamus shows bilateral impairment in ASD as well as between the 
frontal lobe and other cortical regions (Nair et al., 2013; Amihaesei & Stefanachi, 2013; 
Bhat, Acharya, Adeli, Bairy, & Adeli, 2014). Mišić et al. found that long-range functional 
connectivity is reduced in ASD subjects (Mišić et al., 2015). High local connectivity is 
another prominent feature of ASD, prominent in the cerebellum (Anderson et al., 2011; 
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Belmonte et al., 2014; Bhat, Acharya, Adeli, Bairy, & Adeli, 2014). Together, the high local 
connectivity and low long-range connectivity result in atypical information processing 
(Anderson et al., 2011; Bhat, Acharya, Adeli, Bairy, & Adeli, 2014; Mišić et al., 2015). 
Interhemispheric correlation is also significantly reduced in regions with functional relevance 
to ASD, but the largest difference was found in the anterior frontal insula which is a core 
component of social processing networks (Anderson, Rodriguez & Kern, 2011). Dinstein et 
al., found that toddlers with ASD had weak interhemispheric neural synchronization 
(Dinstein et al., 2011). Verbal ability was positively correlated with strength of 
synchronization while severity of ASD was negatively correlated (Dinstein et al., 2011). The 
corpus callosum is also a site of significant abnormality in ASD subjects as its size is 
decreased, resulting in decreased interhemispheric connection (Anderson et al., 2011; 
Rodriguez & Kern, 2011).  
4.Available Treatments 
 Through intervention and support, an individual’s functional independence and 
quality of life can be maximized through learning and development, improved social skills 
and communication, and reductions in disability and comorbidity (Lai, Lombardo, & Baron-
Cohen, 2014). The most commonly used forms of therapy for ASD are Applied Behavior 
Analysis (ABA), developmental models, structured learning techniques, speech therapy, 
social skills therapy, and occupational therapy (Amihaesei & Stefanachi, 2013). Early 
intensive behavioral interventions that are targeted and comprehensive can improve social 
communication skills and reduce anxiety and aggression (Lai, Lombardo, & Baron-Cohen, 
2014). Prescription medications can also be used in the treatment of ASD. The most 
frequently prescribed medications are antidepressants, stimulatory drugs/psychotropes, and 
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antipsychotics (Amihaesei & Stefanachi, 2013). However, none of these drugs target core 
ASD symptoms and instead treat the co-morbidities of ASD such as hyperactivity, anxiety, 
and self-stimulatory behaviors (Wagner & Harony-Nicolas, 2018). Antipsychotic drugs have 
been effective in reducing repetitive and aggressive behaviors in children with ASD (Lai, 
Lombardo, & Baron-Cohen, 2014). Risperidone, an atypical antipsychotic, is the most widely 
prescribed treatment for ASD although it only reduces hyperactivity, aggressive, self-
injurious, and repetitive behaviors and does not improve social deficits (Guastella and 
Hickie, 2016). Risperidone has also been associated with significant side effects including 
weight gain, drowsiness, extrapyramidal side effects, and hormonal changes related to 
galactorrhea, amenorrhea, and gynecomastia (Guastella and Hickie, 2016). To date, no 
biomedical agents have been shown to reliably improve social deficits (Lai, Lombardo, & 
Baron-Cohen, 2014). Some unconventional therapies used in the treatment of ASD are: 
acupuncture, antifungal therapy, art therapy, the Early Start Denver model, therapy with 
dolphins, aerobics, interactive computer programs, facilitated communication, music therapy, 
contact therapy, homeopathy, neuro-feedback, rhythms therapy, and yoga (Amihaesei & 
Stefanachi, 2013). Despite their popularity and significant expense, these treatments have 
little evidence to support their efficacy and are not specified for a subtype of ASD (Guastella 
and Hickie, 2016). All available treatments are either lengthy, expensive, or time-sensitive 
and do not alleviate core symptoms of ASD, highlighting the need for effective and 
accessible interventions that address the core symptoms of ASD. 
5.Animal Models of ASD 
 To establish effective evidence-based interventions for ASD, successful interventions 
in animal models of ASD must be examined. Two common and validated animal models of 
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ASD are the Maternal Immune Activation (MIA) model and the Maternal High Fat Diet 
(MHFD) model, used in the recent evidence to support probiotic intervention. 
Maternal Immune Activation Model 
 The MIA mouse model is based on large epidemiological studies that linked maternal 
infection to increased incidence of autism in offspring (Atladóttir et al., 2010). This model is 
also supported by studies linking ASD risk to familial autoimmune disease and elevated 
levels of inflammatory factors in the maternal blood, placenta, and amniotic fluid (Atladóttir 
et al., 2010; Comi et al., 1999; Abdallah et al., 2013; Brown et al., 2004; Croen et al, 2008). 
Stimulating maternal immune activation in mice triggers global changes in the gut 
microbiome of offspring which is correlated with abnormal behavior, neuropathologies, 
immune dysfunction, and GI impairment (Vuong & Hsiao, 2017). MIA in mice is stimulated 
by injecting pregnant mice with the viral mimic poly (I:C) and results in offspring that 
express core behavioral symptoms and neuropathologies of ASD (Malkova et al., 2012). The 
offspring exhibit dysbiosis of gut microbiota, prominent in alterations of the bacterial classes 
Clostridia and Bacteroidetes (Hsiao et al., 2013). The MIA offspring display ASD-like 
behaviors, impaired intestinal integrity, and altered gut microbiome profiles (Hsiao et al., 
2013). These symptoms are comparable to similar endophenotypes found in subsets of 
individuals with ASD (Hsiao et al., 2013). 
Maternal High Fat Diet Model 
 The MHFD model is based on epidemiological studies that support a link between 
maternal obesity and increased risk of neurodevelopmental disorders, such as ASD in 
offspring (Connolly et al, 2016; Krakowiak et al., 2012; Sullivan). The MHFD triggers 
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abnormal behavior in offspring and is mediated by alterations in the gut microbiome of the 
offspring (Buffington et al., 2016). Buffington et al. found that the MHFD-induced changes 
in the gut microbiome of offspring block long-lasting neural adaptation in the mesolimbic 
dopamine reward system, specifically in the ventral tegmental area (VTA) (Buffington et al., 
2016). These neuronal adaptations enhance the salience of social stimuli and the MHFD-
induced alterations in these neural networks results in social behavioral deficits (Buffington 
et al., 2016). In comparison to offspring from mice fed a regular fat diet, MHFD offspring 
had fewer reciprocal social interactions, impaired sociability, and lack of preference for 
social novelty (Buffington et al., 2016). These offspring also exhibit repetitive behaviors and 
anxiety, symptoms that are also associated with ASD, as well as fewer oxytocin 
immunoreactive neurons in the hypothalamus (Buffington et al., 2016). 
Utilizing these two validated animal models of ASD, two strains of probiotics have 
been shown to successfully ameliorate behavioral and social deficits in affected offspring: 
Bacteroides fragilis and Lactobacillus reuteri. 
 
III. The Current State of Non-Pharmaceutical Interventions 
Complementary and Alternative Medicine 
 Complementary and alternative medicine (CAM) is incredibly popular among 
families with children with ASD (Akins, Angkustsiri, & Hansen, 2010). Examining non-
pharmaceutical interventions is imperative as significant adverse side effects have been 
associated with and increased by some conventional psychiatric medications used in children 
with ASD (Akins, Angkustsiri, & Hansen, 2010). Additionally, families are often inclined to 
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search for more progressive and less expensive interventions, especially outside of the 
medical field. Geographic and economic barriers can limit access to high-quality behavioral 
and educational interventions, leaving families to find alternative forms of intervention 
(Akins, Angkustsiri, & Hansen, 2010). The National Center for Complementary and 
Alternative Medicine (NCCAM, 2013) defines CAM as “a group of diverse medical and 
health care systems, practices, and products that are not generally considered part of 
conventional medicine” (NCCAM, 2013). Complementary medicine is typically defined as 
nontraditional treatments used in conjunction with conventional medicine, such using light 
therapy to treat seasonal affective disorder in tandem with antidepressants (Akins). 
Alternative medicine is defined as being used in place of conventional medicine, such as 
using melatonin instead of sedatives to treat insomnia (Akins, Angkustsiri, & Hansen, 2010). 
The American Academy of Pediatrics defines integrative medicine as “relationship-based 
care that combines mainstream and complementary therapies for which there is some high-
quality scientific evidence of safety and effectiveness to promote health for the whole person 
in the context of his or her family and community” (Kemper, Vohra, & Walls, n.d.). The 
American Academy of Pediatrics also recommends the discussion of CAM with the family of 
every ASD patient (Akins, Angkustsiri, & Hansen, 2010). CAM usage in children with ASD 
is amongst the highest of any population with reported use between 52% and 95% in families 
(Akins, Angkustsiri, & Hansen, 2010). Of families who have children with ASD and use 
CAM treatments, approximately 50-70% choose a biologically based CAM treatment (Akins, 
Angkustsiri, & Hansen, 2010). Parents of children with ASD reported current use of an 
average of four treatment modalities and 80% reported some form of dietary intervention 
(Lange, Hauser, & Reissmann, 2015). Qualitative studies have found that receiving outdated 
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information for conventional systems of care, limited provider knowledge of their child’s 
condition, parental frustration with discouraging prognoses, and attempts to construct an 
alternative identity for their children and themselves increase CAM usage by parents of 
children with disabilities (Akins, Angkustsiri, & Hansen, 2010). These findings highlight the 
desire for families to gain more control over medical decision-making (Akins, Angkustsiri, & 
Hansen, 2010). This desire coupled with geographic and economic barriers create a need for 
effective non-pharmaceutical interventions in the treatment of ASD. 
 With the rise of the internet, online ASD support communities have become popular, 
allowing parents to engage with other parents facing similar struggles and ASD-specific 
information (Akins, Angkustsiri, & Hansen, 2010). However, internet usage also increases 
families’ exposure to targeted marketing, testimonials, and unproven claims that could look 
promising in the treatment of ASD (Akins, Angkustsiri, & Hansen, 2010). These ineffective 
treatments exploit desperate parents and can even be dangerous. Some examples of dubious 
popular treatments with negative side effects are: chelation therapy, antifungal agents, 
hyperbaric oxygen therapy, and immune therapies including intravenous and oral Ig (Akins, 
Angkustsiri, & Hansen, 2010). To date, chelation therapy, when used to treat symptoms of 
ASD, has been linked with several deaths (Akins, Angkustsiri, & Hansen, 2010). There are 
also many other purported treatments that are considered generally safe, but their efficacy is 
unknown or even disproven such as use of multivitamins, secretin, and various amino acid 
therapies (Akins, Angkustsiri, & Hansen, 2010). 
 Families of individuals with ASD are often searching for more effective alternatives 
to pharmaceuticals. The high use of CAM shows that families are eager to do all they can and 
desire to have more control over their situation. Additionally, some families cannot afford 
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expensive treatments or are unable to access them, which also leads to higher CAM usage. 
Instead of trying to suppress this phenomenon, researchers must try to meet the needs of 
these families by creating an accessible and affordable alternative to pharmaceuticals or 
lengthy behavioral therapy sessions. Due to increasing misinformation, the families of ASD 
individuals are susceptible to making poor medical choices for their child, despite their best 
intentions. Thus, the need for evidence-based intervention is imperative.  
Efficacy of Gluten Free and Casein Free Diets 
 A product of misinformation, the gluten free and casein free diet (GFCF) has become 
one of the most popular CAM treatments in children with ASD (Akins, Angkustsiri, & 
Hansen, 2010). The GFCF diet is utilized in the treatment of ASD in 29% of families that use 
dietary interventions; approximately 80% of families with ASD individuals (Lange, Hauser, 
& Reissmann, 2015). The rationale for this diet remains unproven and is based on the “opioid 
excess” theory which claims that individuals with ASD have impaired ability to break down 
dietary proteins in gluten and casein, and that this results in the formation of opioid-like 
peptides that cross the blood brain barrier (BBB) and contribute to the neurobehavioral 
symptoms of autism (Akins, Angkustsiri, & Hansen, 2010). Parents have claimed that their 
child’s GI symptoms (54%), concentration and attention (42%), communication (29%), and 
social interaction (25%) improved after implementation of the GFCF diet (Lange, Hauser, & 
Reissmann, 2015). However, it is important to address the measurement bias within these 
findings as the parents were not blinded to the treatment and are likely hoping for their 
child’s symptoms to improve, thus influencing their observations. The GFCF diet can be 
difficult to implement as families face challenges such as increased food preparation time, 
increased food-related expenses, and children refusing to eat the dietary selections (Akins, 
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Angkustsiri, & Hansen, 2010). Additionally, further dietary restriction in a child with an 
already limited food repertoire can induce negative behavioral and biological side effects 
(Akins, Angkustsiri, & Hansen, 2010). In a study by Ghalichi et al., they showed that there 
may be some potential of the GF diet to alleviate stereotyped behaviors and improve social 
communication and interaction in some children with ASD (Ghalichi, Ghaemmaghami, 
Malek, & Ostadrahimi, 2016). However, it is important to note that, once again, the parents 
of the patients, who rated their child’s symptoms, were not blinded to the intervention and 
thus could have been influenced by their awareness (Ghalichi, Ghaemmaghami, Malek, & 
Ostadrahimi, 2016). Lange et al. did an in-depth meta-analysis of studies about the 
intervention of GFCF diets on ASD symptoms (Lange, Hauser, & Reissmann, 2015). They 
evaluated eight published case studies that included anecdotal case reports that attempted to 
establish a casual role of gluten and casein in the pathology of ASD (Lange, Hauser, & 
Reissmann, 2015). Lange et al. found that none of these studies used an appropriate 
experimental control (Lange, Hauser, & Reissmann, 2015). It was also noted that all but two 
studies found evidence of positive dietary effects of the GFCF diet for at least some of the 
measures assessed and the two studies with null results were the case studies that met the 
largest number of quality indicators of experimental validity (Lange, Hauser, & Reissmann, 
2015). Lange et al, states that none of the case studies were conduced with adequate 
scientific rigor and thus, the results of the studies can only be regarded as weak evidence at 
best (Lange, Hauser, & Reissmann, 2015). Common issues included measurement bias, as a 
result of relying on the subjective ratings of parents not blinded to the treatment, and lack of 
appropriate control groups (Lange, Hauser, & Reissmann, 2015). Although the GFCF diet is 
popular and there are a multitude of positive reviews from parents regarding its effects, most 
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scientific studies have failed to confirm significant therapeutic effects (Lange, Hauser, & 
Reissmann, 2015). It has been shown that there is an association between the casein-free diet 
and bone loss in children, an alarming side effect that must be acknowledged with regard to 
parental desire to implement the GFCF diet (Hediger et al., 2008). However, there may be a 
possibility that there are specific subtypes of autism (possibly due to different genesis) that 
may be sensitive and responsive to such dietary elements (Whiteley, 2017). As a concluding 
thought, Lange et al., suggests that a GFCF diet should only be administered if an allergy or 
intolerance to nutritional gluten or casein is diagnosed and present in the child with ASD 
(Lange, Hauser, & Reissmann, 2015). 
 With the widespread prevalence of misinformation and the susceptibility of desperate 
parents who want to help their children with ASD, evidence-based non-pharmaceutical 
intervention is an incredibly important area of interest as it may help parents overcome 
geographic and economic barriers and satisfy their desire for control and self-determination. 
Additionally, an intervention based on strong evidence may prevent families from enduring 
the financial and biological repercussions of implementing popular dietary interventions, 
such as the GFCF diet, that have yet to be scientifically proven as effective. 
 
IV. Probiotics of Interest 
 The two probiotic strains of interest in this proposed treatment of ASD are 
Bacteroides fragilis and Lactobacillus reuteri. 
1.Bacteroides Fragilis 
 Previously shown to correct colitis in infants, B. fragilis gained interest as a potential 
probiotic intervention for individuals with ASD (Hsiao et al., 2013). In a groundbreaking 
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experiment conducted by Hsiao et al, B. fragilis was discovered to correct gut permeability, 
alter microbial composition, and ameliorate deficits in communicative, stereotypic, anxiety-
like, and sensorimotor behaviors in the offspring of MIA mice, a reliable animal model of 
ASD (Hsiao et al., 2013). The MIA offspring exhibited altered serum metabolites of gut 
origin that were normalized by B. fragilis treatment (Hsiao et al., 2013). Two of these 
metabolites, 4EPS and indolepyruvate, are potentially associated with ASD (Hsiao et al., 
2013). Intestinal epithelial hyperpermeability, as well as altered levels of tight junction 
proteins and cytokines, were also corrected by B. fragilis treatment. Hsiao et al. suggests that 
B. fragilis is able to correct leaky gut by directly targeting tight junction expression, cytokine 
production, and/or microbiome composition (Hsiao et al., 2013). This is consistent with the 
role of gut microbiota in regulating metabolic homeostasis and intestinal permeability (Hsiao 
et al., 2013). However, despite the improvements in communicative, repetitive, anxiety-like, 
and sensorimotor behaviors, B. fragilis treatment fails to ameliorate deficits in sociability and 
social preference (Hsiao et al., 2013). 
2.Lactobacillus Reuteri 
 In a revolutionary and replicated study, Buffington et al. and Sgritta et al. found that 
oral treatment with L. reuteri corrected oxytocin levels and synaptic dysfunction in the VTA 
of MHFD offspring, a validated animal model for ASD (Buffington et al., 2016; Sgritta et al., 
2019). Buffington et al. was the first to complete this study and Sgritta et al. replicated this 
study and examined possible mechanisms. Treatment with L. reuteri selectively ameliorates 
social deficits in genetic, environmental, and idiopathic ASD models (Sgritta et al., 2019). 
MHFD offspring who received L. reuteri treatment showed increases in reciprocal social 
interactions, sociability, and preference for social novelty (Buffington et al., 2016). Only 
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social deficits are ameliorated with L. reuteri treatment, no other behavioral endophenotypes 
associated with ASD were affected (Buffington et al., 2016). Sgritta et al. also found that 
treatment with L. reuteri corrects social deficits in several ASD mouse models (Sgritta et al., 
2019). The method in which L. reuteri alleviates social deficits was discovered to be via the 
vagus nerve (Sgritta et al., 2019). A vagotomy prevented amelioration of social deficits 
despite L. reuteri treatment (Sgritta et al., 2019). Vagal nerve fibers project to the 
paraventricular nuclei (PVN), where oxytocin is produced, and subdiaphragmatic vagotomy 
blocks this neural activity in the PVN (Sgritta et al., 2019). Additionally, Sgritta et al. 
revealed that the effects of L. reuteri are not mediated by the restoration of the gut 
microbiome as monocolonization in germ-free mice still successfully restored social 
behaviors (Sgritta et al., 2019). Thus, L. reuteri treatment ameliorates social deficits and 
related changes in synaptic function within the social reward neural circuits, in a vagus nerve 
and oxytocin dependent manner (Sgritta et al., 2019). 
The success of these probiotic interventions is contributable to two biological systems 
linked to ASD pathology; the gastrointestinal system and the oxytocin system. To understand 
the efficacy of B. fragilis in reducing repetitive behaviors, the relationship between ASD and 
the GI system needs to be analyzed. Similarly, the oxytocin system must be addressed to 
understand the efficacy of L. reuteri in ameliorating social deficits. 
 
V. ASD and the GI system 
 An extensive study of over 14,000 individuals with ASD showed a higher prevalence 
of irritable bowel syndrome (IBD) and other GI disorders in ASD subjects compared to 
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controls (Kohane et al., 2012). The most reported GI symptoms in children with ASD are 
“any GI symptom/aggregate of symptoms” (46.8%), constipation (22.0%), chronic diarrhea 
(16.2%), and abdominal pain (14.0%) (Holingue et al., 2018). A study from the Childhood 
Autism Risks from Genetics and Environment (CHARGE) revealed that frequency of GI 
symptoms was associated with greater social withdrawal, stereotypy, irritability, and 
hyperactivity (Vuong & Hsiao, 2017). Additional GI abnormalities associated with ASD 
include altered gut microbiome composition, overproduction of bacterial metabolites, and 
increased GI mucosa permeability (Azhari, Azizan, & Esposito, 2018). Adams et al. found 
that ASD symptom severity is positively correlated with severity of GI dysfunction, a link 
supported by various studies (Adams et al., 2011; Tomova et al., 2015; Yang et al., 2018).  
The bidirectional relationship between the brain and the gut, also referred to as the 
gut-brain axis, can influence development, neurochemistry, gene expression, and brain 
function (Tomova et al., 2015). The gut microbiome, the most significant part of the GI 
system, is comprised of 500-1000 denizen species representing 7,000-40,000 different strains 
spanning 1800 genera and total to approximately 1x1013-1x1014 microorganisms (Rosenfeld, 
2015). The gut microbiota is essential for digestion as it synthesizes various vitamins and 
cofactors, and metabolizes complex lipids, proteins, and carbohydrates, even those that are 
indigestible by the host (Rosenfeld, 2015).  
Subjects with ASD have been repeatedly reported to have significant differences in 
species richness and diversity, across phylum and species with a marked decrease in bacterial 
diversity (Sharon, Sampson, Geschwind, & Mazmanian, 2016; Tomova et al., 2015; Kang et 
al., 2017). A proposed explanation for this phenomenon is that many children with ASD 
undergo increased oral antibiotic treatment during the first 3 years of life, which could 
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destabilize their gut microbiome and create opportunities for competitive potential pathogens 
to contribute to ASD severity (Kang et al., 2017). The gut microbiome becomes stable 
between 6 and 36 months of life, thus the use of antibiotics could disrupt this critical process 
(Mangiola et al., 2016). Children with ASD exhibit alteration in the Bacteroidetes/Firmicutes 
ratio, even in comparison to neurotypical children with GI problems (Tomova et al., 2015). 
Elevated levels of Clostridia, Desulfovibrio, Sutterella, Bacteriodetes, Lactobacillus, 
Prevotella, Ruminococcus, and Alcaligenaceae have been found in the gut microbiomes of 
ASD subjects (Tomova et al., 2015; Sharon, Sampson, Geschwind, & Mazmanian, 2016; 
Rosenfeld, 2015; Mangiola et al., 2016). There is a very strong correlation between levels of 
Desulfovibrio with the severity of ASD symptoms (Tomova et al., 2015). High levels of 
Clostridia correlated with increased GI problems, within the ASD group (Ding, Taur, & 
Walkup, 2017).  
Gut dysbiosis can impact host immunity and neurobehavioral responses (Rosenfeld, 
2015; Tomova et al., 2015). The gut microbiome directly and indirectly affects the intestinal 
epithelium which, through the local mucosal immune system and enteric nervous system, 
affects neuronal pathways from the gut to the brain (Tomova et al., 2015). Neuro-active 
neurotransmitters, such as GABA, and short chain fatty acids (SCFA) are synthesized by the 
gut microbiome and, through interactions upon the HPA (hypothalamic-pituitary-adrenal) 
axis, can alter cognition and mood (Tomova et al., 2015). It has been suggested that 
alterations in the gut microbiome could influence long-lasting changes in synaptic efficacy in 
the mesolimbic dopamine reward system underlying social behaviors (Sgritta et al., 2019). 
The epithelial gut barrier is critical to proper function as it controls the flow of 
molecules between the GI tract and bloodstream and is maintained by tight junctions (Ding, 
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Taur, & Walkup, 2017). These junctions can be affected by gut microbiota and their ligands 
and can result in compromised integrity of the epithelial barrier, termed “leaky gut” (Ding, 
Taur, & Walkup, 2017). Increased intestinal permeability can be problematic for the host as 
it may allow for passage of bacteria, toxins, and metabolites into the bloodstream (Ding, 
Taur, & Walkup, 2017). Increased bacterial translocation and direct measurements show 
increased intestinal permeability in individuals with ASD (Whiteley, 2017; Hsiao et al., 
2013). In addition, altered levels of SCFAs, produced by gut microbiota, are capable of 
passing through the BBB and have been noted in individuals with ASD (Azhari, Azizan, & 
Esposito, 2018). Increased levels of SCFAs are notable because they can impact CNS 
function via changes in neurotransmitter synthesis and release, mitochondrial function, 
immune activation, lipid metabolism, and gene expression (Ding, Taur, & Walkup, 2017). 
These neuroactive compounds have the ability to alter behavior once they pass through the 
BBB and are in part, responsible for the abnormal behaviors prevalent in ASD. The 
bidirectional relationship between the gut microbiome and the brain that allows for GI 
impairments to result in abnormal behavior is depicted in Figure 2. 
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Figure 2. The bidirectional relationship between the gut microbiome and the brain in the 
pathology of ASD (Li, Han, Dy, & Hagerman, 2017). 
 
VI. The Role of Oxytocin in ASD 
 Oxytocin is a nine-amino-acid neuropeptide produced in the hypothalamus with well-
established neuroendocrine functions and remarkable influence over prosocial behavior 
(Young & Barrett, 2015; Jones et al., 2017; Parker et al., 2017; Peñagarikano et al., 2015). 
Oxytocin binds to four receptors: OXTR, V1AR, V1BR, and V2R though its prosocial 
effects are associated with OXTR and V1AR (Parker et al., 2017). Oxytocin influences social 
cognition, social behavior, fear conditioning, social attachment, pair bonding, and aggression 
(Jones et al., 2017; Yamasue & Domes, 2018). Oxytocin expressing neurons in the PVN 
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project to brain regions including the amygdala, hippocampus, and frontal cortex, that are 
important in behaviors such as fear, memory, sociability, and attention (Peñagarikano et al., 
2015). Oxytocin increases the salience of social stimuli by activating VTA neurons and has 
anxiolytic effects (Young & Barrett, 2015; Buffington et al., 2016; Jones et al., 2017). 
Altered genotypes in oxytocin receptor genes have been associated with ASD symptomology 
(Yamasue & Domes, 2018). In neurotypical subjects, there is a gradual shift of GABA action 
from excitatory to inhibitory during development, termed “the GABA switch,” that when 
interrupted, leads to ASD symptomology in animal models (Wagner & Harony-Nicolas, 
2018). 
 Numerous studies regarding intranasal oxytocin intervention in ASD have been 
completed. A replicated finding, intranasal administration of oxytocin temporarily enhances 
social cognition, empathy, and reciprocity in individuals with ASD and increase social 
behaviors such as eye gaze, feelings of rest, and recognition of affective speech (Young & 
Barrett, 2015; Jones et al., 2017). Response to oxytocin treatment could be predicted by 
pretreatment blood oxytocin levels, which suggests that a specific subset of the ASD 
population could be more susceptible to improvements (Parker et al., 2017). The prosocial 
effects of oxytocin have also been well-documented in animal models of ASD (Teng et al., 
2016; Peñagarikano et al., 2015; Wagner & Harony-Nicolas, 2018). 
 It is widely accepted that oxytocin administration is well-tolerated in humans and in 
ASD populations specifically (Cai, Feng, & Yap, 2018; Parker et al., 2017). However, 
possible adverse effects have been noted, such as altered sexual development, anaphylactic 
shock, arrhythmia, nausea, and vomiting (Bales et al., 2013; Cai, Feng, & Yap, 2018). The 
preferred method of targeting peptides to the brain is through intranasal administration, as it 
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is less invasive of a procedure (Peñagarikano et al., 2015). Guastella and Hickie, noted that 
children with poor verbal communication have difficulty tolerating nasal sprays, in their 
unpublished data (Guastella and Hickie, 2016). Nasal discomfort, tiredness, irritability, 
diarrhea, and skin irritation were the most common adverse reactions in children with ASD 
using the intranasal method of oxytocin administration (Cai, Feng, & Yap, 2018). Still, there 
are many discrepancies that need to be dealt with such as optimization of administration 
route, dose, and treatment duration (Yamasue & Domes, 2018).  
 
VII. The Current Study 
 Both B. fragilis and L. reuteri, bacterial strains present in the gut microbiome, 
improve core symptoms of ASD (Hsiao et al., 2013; Buffington et al., 2016; Sgritta et al., 
2019). B. fragilis improves only restrictive and repetitive behaviors while L. reuteri improves 
only social deficits (Hsiao et al., 2013; Buffington et al., 2016; Sgritta et al., 2019). With a 
combination of the two probiotic strains, both repetitive behaviors and social deficits could 
be targeted. I propose that probiotic intervention with B. fragilis will decrease restrictive and 
repetitive behaviors in individuals with ASD. Similarly, I also expect that probiotic 
intervention with L. reuteri will improve social deficits in individuals with ASD. I 
extrapolate that, due to additive interaction effects, probiotic intervention with these two 
bacterial strains will ameliorate both restrictive and repetitive behaviors and social deficits. 
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VIII. Method 
Participants 
 The participants will be children from the ages of 5 to 13 that have been clinically 
diagnosed with ASD and have no other neurological comorbidities.  
Materials 
Bacteroides fragilis in capsule form, Lactobacillus reuteri in capsule form, placebo 
capsules 
Measures 
Repetitive and Restrictive Behavior 
Repetitive and restrictive behavior will be measured by the Repetitive Behavior Scale 
– Revised (RBS-R). This scale measures the severity of repetitive behaviors in individuals 
with ASD. The 43 items are organized into six subscales: stereotyped behavior, self-injurious 
behavior, compulsive behavior, ritualistic behavior, sameness behavior, and restricted 
behavior (Scahill et al., 2015). The items are scored on a four-point scale from zero to three 
(0=never, 1=mild, 2=moderate, 3=severe) (Scahill et al., 2015). I propose to use the RBS-R 
total score, out of 129, to measure repetitive and restricted behavior.  
Social Deficits 
 Social ability, and consequently social deficits, will be measured by the Social 
Responsiveness Scale (SRS-2). This scale assesses the individual’s ability to engage in 
appropriate reciprocal social interaction and communication (Frazier et al., 2014). The SRS-2 
is comprised of 5 subscales: social awareness (assesses an individual’s ability to recognize 
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social cues of others), social cognition (assesses interpretation of social behavior), social 
communication (assesses reciprocal communication in social situations), and autistic 
mannerisms (assesses stereotypy and restrictive interests) (Frazier et al., 2014; Bruni, 2014). 
Items are scored on a scale from one (never) to four (almost always). The results of the SRS-
2 are reported in T-score format (M=50, SD=10) (Bruni, 2014). The SRS-2 total score is the 
most reliable form of assessing social deficits in individuals with autism (Bruni, 2014). Thus, 
I will use this scale to quantify social deficit in ASD individuals in the current study.  
Procedures 
 There will be four experimental groups. The first is the control group who will take 
two placebo capsules. The second group will take one capsule of B. fragilis and one placebo 
capsule. The third group will take one capsule of L. reuteri and one placebo capsule. The 
fourth group will take one capsule of B. fragilis and one capsule of L. reuteri. All groups will 
take the capsules orally, once a day with breakfast. Caretakers will assess the participants 
using the RBS-R and the SRS-2 scales three times a week. The children will also participate 
in an academic medical center-based program for families with ASD that focuses on 
integrations of interventions, clinical trials, and childcare. The children will visit the center 
weekly, allowing blinded researchers to assess the participants using the RBS-R and SRS-2 
scales. The study will proceed for the duration of a year, allowing for short term and long-
term observations to be made. 
Ethics 
 As this study involves human participants, the study must be approved by the 
Institutional Review Board at Scripps College in accordance with the currently applicable 
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U.S. Public Health Service Guidelines. Additionally, this study involves children with 
cognitive impairment and they are considered a protected and vulnerable population. Thus, 
informed consent will need to be provided by the legal guardians of the children. The 
participants must be children with ASD as that is the target population of this intervention 
and its efficacy must be examined in the ASD population. Furthermore, most treatment 
interventions for ASD occur in childhood, underscoring the importance of evaluating the 
efficacy of this probiotic intervention in children with ASD. 
 
IX. Expected Results 
 Those in the control group will see no improvement in repetitive behavior or social 
deficits. Those receiving only B. fragilis will see improvements in repetitive behavior but not 
in social deficits. Those receiving only L. reuteri will see improvements in social deficits but 
not in repetitive behavior. Those taking both strains will see improvements in both repetitive 
behavior and social deficits. 
The mean RBS-R score for individuals with autism is 33.14 (Lam). All experimental 
groups will begin the intervention with mean RBS-R scores of 33.14. Those receiving the 
placebo or L. reuteri interventions will not see an improvement in repetitive behaviors and 
their RBS-R scores will not be significantly altered. The placebo intervention group will end 
with a mean RBS-R score of 33.67 and the L. reuteri intervention group will end with a mean 
RBS-R score of 34.59. Those receiving the B. fragilis or both probiotic strains intervention 
will see a reduction of repetitive behaviors, manifesting in lower mean RBS-R scores. The B. 
fragilis intervention group will end with a mean RBS-R score of 15.47 and the intervention 
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with both probiotic strains will end with a mean RBS-R score of 16.13. These expected 
scores are represented in Figure 3. 
 
Figure 3. Change in RBS-R scores after differing interventions. 
SRS-2 T-scores are correlated with severe, moderate, and mild social deficits. Severe 
and clinically significant social deficits are indicated by T-scores 76 or higher (Bruni, 2014). 
The moderate range of T-scores falls between 66 and 75 and demonstrates some clinically 
significant social deficits (Bruni, 2014). Scores between 60 to 65 indicate mild social 
impairments (Bruni, 2014). 
The mean SRS-2 T-score of all participants before intervention will be 77. Those 
receiving the placebo intervention will have no significant reduction in mean SRS-2 T-scores 
and will end the intervention with a T-score of 76. Those receiving the B. fragilis 
intervention will also see no improvement in social deficits, manifesting in a final SRS-2 T-
score of 77. The individuals receiving the L. reuteri intervention will see significant 
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improvement in social deficits and end with a significantly lower SRS-2 T-score of 62. The 
individuals receiving the intervention with both probiotic strains will also see a significantly 
lower mean SRS-2 T-score of 63 as well as improvements in social deficits. Thus, the 
placebo and B. fragilis interventions will not affect social deficits but the L. reuteri and 
combined strains intervention will improve social deficits. These expected scores are 
represented in Figure 4.  
 
Figure 4. Change in SRS-2 scores after differing interventions. 
 
X. Discussion 
Implications 
 If probiotic intervention with B. fragilis and L. reuteri is found to be viable and 
effective, it would significantly affect the lives of individuals with ASD and their families. 
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This would become the first intervention to target the core symptoms of ASD, repetitive 
behavior and social deficits. Furthermore, it could substantially decrease the economic 
burden associated with ASD. The estimated total costs per year for children with ASD falls 
between $11.5 - $60.9 billion (2011 US dollars) which includes indirect and direct expenses 
such as, medical care, loss of parental economic productivity, and special education (CDC, 
2018). The most effective intervention to date, early intensive behavioral therapy, can cost 
nearly $40,000 - $60,000 per year (CDC, 2018). If this probiotic intervention is found to be 
effective, it could provide a more economically accessible avenue of intervention for 
individuals with ASD, as probiotic production costs are notably lower than pharmaceutical 
production costs and behavioral therapy sessions. Additionally, daily oral administration 
would take less time than in-person therapy sessions which could prevent the loss of parental 
economic productivity. Although probiotic intervention would not necessarily or directly 
improve the general health of an individual with ASD, it could improve behaviors that are 
indirectly detrimental to health, such as maintaining a narrow food repertoire and 
uncontrolled motor stereotypies. This reduction in restrictive and repetitive behavior would 
reduce the need for individuals to resort to costly medications associated with negative side 
effects, such as risperidone, which is used to treat irritability in individuals with ASD in the 
hopes of preventing injurious and self-injurious motor stereotypies. Another pertinent issue 
that has yet to be addressed by current interventions is the treatment of adults with ASD. 
Most of the available treatments for ASD are targeted towards children, resulting in a 
significant decline in effectiveness with increasing age. Teng et al., found that oxytocin 
administration improved social deficits in both young and adult mice, in an age-independent 
manner (Teng et al., 2016). Since L. reuteri administration stimulates oxytocin production, it 
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is comparable to and less invasive than intranasal oxytocin administration. Thus, it could be 
expected that the prosocial effect of L. reuteri would also be age-independent. If this were 
the case, this would allow adults with ASD to receive effective treatment for their social 
communication deficits which could potentially lead to an increase in independence, both 
economically and physically. However, if this combined probiotic treatment of B. fragilis 
and L. reuteri were to be established as ineffective in humans, the biological, economical, 
and social state of individuals with ASD would remain the same and there would be no 
interventions targeted towards the core symptoms of ASD. 
Possible Complications 
 A few different factors could complicate the application of this probiotic intervention 
in the treatment of ASD. Most importantly, the most effective dosages of B. fragilis and L. 
reuteri have yet to be determined. There is potential that the most effective dose could vary 
among specific populations of individuals with ASD. It has been determined that there are 
specific subsets of individuals with ASD, attributed to different geneses, with predispositions 
to comorbidities and intervention effectiveness (Parker et al., 2017). It is possible that a 
specific endotype of individuals with ASD will be more susceptible to improvements through 
probiotic intervention, although biological markers differentiating these subsets have not yet 
been determined. Additionally, it is possible that there is optimum dosage ratio of B. fragilis 
to L. reuteri as both strains, to be effective, must colonize the gut microbiome and little is 
known about whether there would be competition between the two strains during the 
colonizing process. The optimal length of intervention could differ between the two strains 
and it is not yet known if improvements in behavioral and social deficits are dependent upon 
continued oral administration. 
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Future Studies 
It is imperative that studies ascertain the optimal clinical dosage of B. fragilis and L. 
reuteri, both independently and concurrently. These findings would lay the foundation for 
future improvements and adjustments of this intervention method. In addition, future studies 
must examine differing lengths of probiotic intervention and the following period after 
discontinuation to explore the temporal dependency of improvements upon daily 
administration. Furthermore, Hsiao et al., found that improvements in repetitive and 
restrictive behavior could be induced by other probiotic strains and was not singularly 
dependent upon B. fragilis intervention (Hsiao et al., 2013). The probiotic strain Bacteroides 
thetatiotacomicron also significantly improved restrictive and repetitive behaviors in MIA 
offspring although the administration of the probiotic strain Enterococcus faecalis did not 
have any effect on behavior, signifying that there is some level of specificity to efficacy of 
probiotic intervention. 
 
XI. Conclusions 
 Treatment with B. fragilis decreases restrictive and repetitive behaviors by correcting 
intestinal epithelial hyperpermeability, cytokine production, and gut microbiome composition 
(Hsiao et al., 2013). B. fragilis treatment targets the tight junction protein expression of the 
intestinal epithelium, and improves intestinal barrier integrity (Hsiao et al., 2013). This 
decreases leakage of neuro-active molecules into the blood that can lead to abnormal 
behaviors (Hsiao et al., 2013). Treatment with L. reuteri ameliorates social deficits by 
stimulating oxytocin production via the vagus nerve which increases oxytocin levels and 
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restores social interaction-induced synaptic plasticity (Sgritta et al., 2019). The increase in 
oxytocin levels promotes prosocial behavior and increases reciprocal social interactions, 
sociability, and preference for social novelty (Sgritta et al., 2019). It is hypothesized that 
treatment with both probiotic strains will decrease behavioral and social deficits, the core 
symptoms of ASD that have not yet been addressed by available interventions to date. 
 
 
 
XII. Acknowledgements 
I would like to thank Dr. Stacey Wood for her continuous support and encouraging guidance 
throughout this process. I would also like to thank Dr. John Milton for his thoughtful 
guidance and input. Additionally, I would like to thank the W. W. Keck Science department 
for this opportunity. 
 
XIII. Literature Cited 
Abdallah, M. W., Larsen, N., Grove, J., Nørgaard-Pedersen, B., Thorsen, P., Mortensen E. 
L., & Hougaard D. M. (2013). Amniotic fluid inflammatory cytokines: Potential markers of 
immunologic dysfunction in autism spectrum disorders. The World Journal of Biological 
Psychiatry, 14(7). https://doi.org/10.3109/15622975.2011.639803  
Adams, J. B., Johansen, L. J., Powell, L. D., Quig, D., & Rubin, R. A. (2011). 
Gastrointestinal flora and gastrointestinal status in children with autism – comparisons to 
typical children and correlation with autism severity. BMC Gastroenterology, 11(1), 22. 
https://doi.org/10.1186/1471-230X-11-22 
Akins, R. S., Angkustsiri, K., & Hansen, R. L. (2010). Complementary and alternative 
medicine in autism: An evidence-based approach to negotiating safe and efficacious 
interventions with families. Neurotherapeutics, 7(3), 307–319. 
https://doi.org/10.1016/j.nurt.2010.05.002 
40 
 
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental 
disorders (5th ed.). Arlington, VA: Author. 
Amihaesei, I. C., & Stefanachi, E. (2013). Autism, and Overwhelming Condition: History, 
Etiopathogenesis, Types, Diagnosis, Therapy, and Prognosis. The Medical-Surgical Journal, 
117(3), 654–661. 
Anderson, J. S., Druzgal, T. J., Froehlich, A., DuBray, M. B., Lange, N., Alexander, A. L., 
… Lainhart, J. E. (2011). Decreased Interhemispheric Functional Connectivity in Autism. 
Cerebral Cortex, 21(5), 1134–1146. https://doi.org/10.1093/cercor/bhq190 
Atladóttir, H.Ó., Thorsen, P., Østergaard, L. et al. J Autism Dev Disord (2010) 40: 1423. 
https://doi.org/10.1007/s10803-010-1006-y 
Azhari, A., Azizan, F., & Esposito, G. (2018). A systematic review of gut-immune-brain 
mechanisms in Autism Spectrum Disorder. Developmental Psychobiology. 
https://doi.org/10.1002/dev.21803 
Bales, K. L., Perkeybile, A. M., Conley, O. G., Lee, M. H., Guoynes, C. D., Downing, G. M., 
Yun, C. R., Solomon, M., Jacob, S., & Mendoza, S. P. (2013). Chronic Intranasal Oxytocin 
Causes Long-Term Impairments in Partner Preference Formation in Male Prairie Voles. 
Biological Psychiatry, 74(3). https://doi.org/10.1016/j.biopsych.2012.08.025 
Belmonte, M. K., Allen, G., Beckel-Mitchener, A., Boulanger, L. M., Carper, R. A., & 
Webb, S. J. (2004). Autism and Abnormal Development of Brain Connectivity. Journal of 
Neuroscience, 24(42), 9228–9231. https://doi.org/10.1523/JNEUROSCI.3340-04.2004 
Bhat, S., Acharya, U. R., Adeli, H., Bairy, G. M., & Adeli, A. (2014). Autism: cause factors, 
early diagnosis and therapies. Reviews in the Neurosciences, 25(6). 
https://doi.org/10.1515/revneuro-2014-0056 
Brown, A. S., Hooton, J., Schaefer, C. A., Zhang, H., Petkova, E., Babulas, V., … Susser, E. 
S. (2004). Elevated Maternal Interleukin-8 Levels  and Risk of Schizophrenia in Adult 
Offspring. American Journal of Psychiatry, 161(5), 889–895. 
https://doi.org/10.1176/appi.ajp.161.5.889 
Bruni, T. P. (2014). Test Review: Social Responsiveness Scale–Second Edition (SRS-2). 
Journal of Psychoeducational Assessment, 32(4), 365–369. 
https://doi.org/10.1177/0734282913517525 
Buffington, S. A., Di Prisco, G. V., Auchtung, T. A., Ajami, N. J., Petrosino, J. F., & Costa-
Mattioli, M. (2016). Microbial Reconstitution Reverses Maternal Diet-Induced Social and 
Synaptic Deficits in Offspring. Cell, 165(7), 1762–1775. 
https://doi.org/10.1016/j.cell.2016.06.001 
41 
 
Cai, Q., Feng, L. and Yap, K. Z. (2018), Systematic review and meta‐analysis of reporte d 
adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder. 
Psychiatry Clin. Neurosci., 72: 140-151. doi:10.1111/pcn.12627 
CDC. (2018, May 3). Basics About Autism Spectrum Disorder (ASD) | NCBDDD | CDC. 
Retrieved March 9, 2019, from Centers for Disease Control and Prevention website: 
https://www.cdc.gov/ncbddd/autism/facts.html 
 Comi, A. M., Zimmerman, A. W., Frye, V. H., Law, P. A., & Peeden, J. N. (1999). Familial 
Clustering of Autoimmune Disorders and Evaluation of Medical Risk Factors in Autism. 
Journal of Child Neurology, 14(6), 388–394. https://doi.org/10.1177/088307389901400608 
Connolly, N., Anixt, J., Manning, P., Lin, D. P.-I., Marsolo, K. A., & Bowers, K. (2016). 
Maternal metabolic risk factors for autism spectrum disorder—An analysis of electronic 
medical records and linked birth data. Autism Research, 9(8), 829–837. 
https://doi.org/10.1002/aur.1586 
Croen, L. A., Braunschweig, D., Haapanen, L., Yoshida, C. K., Fireman, B., Grether, J. K., 
… Van de Water, J. (2008). Maternal Mid-Pregnancy Autoantibodies to Fetal Brain Protein: 
The Early Markers for Autism Study. Biological Psychiatry, 64(7), 583–588. 
https://doi.org/10.1016/j.biopsych.2008.05.006 
Ding, H. T., Taur, Y., & Walkup, J. T. (2017). Gut Microbiota and Autism: Key Concepts 
and Findings. Journal of Autism and Developmental Disorders, 47(2), 480–489. 
https://doi.org/10.1007/s10803-016-2960-9 
Dinstein, I., Pierce, K., Eyler, L., Solso, S., Malach, R., Behrmann, M., & Courchesne, E. 
(2011). Disrupted Neural Synchronization in Toddlers with Autism. Neuron, 70(6), 1218–
1225. https://doi.org/10.1016/j.neuron.2011.04.018 
Falco, M. (2014). Autism rates now 1 in 68 U.S. children: CDC. 
https://www.cnn.com/2014/03/27/health/cdc-autism/index.html 
Frazier, T. W., Ratliff, K. R., Gruber, C., Zhang, Y., Law, P. A., & Constantino, J. N. (2014). 
Confirmatory factor analytic structure and measurement invariance of quantitative autistic 
traits measured by the Social Responsiveness Scale-2. Autism, 18(1), 31–44. 
https://doi.org/10.1177/1362361313500382 
Gilman, S. R., Iossifov, I., Levy, D., Ronemus, M., Wigler, M., & Vitkup, D. (2011). Rare 
De Novo Variants Associated with Autism Implicate a Large Functional Network of Genes 
Involved in Formation and Function of Synapses. Neuron, 70(5), 898–907. 
https://doi.org/10.1016/j.neuron.2011.05.021 
Ghalichi, F., Ghaemmaghami, J., Malek, A., & Ostadrahimi, A. (2016). Effect of gluten free 
diet on gastrointestinal and behavioral indices for children with autism spectrum disorders: a 
42 
 
randomized clinical trial. World Journal of Pediatrics, 12(4), 436–442. 
https://doi.org/10.1007/s12519-016-0040-z 
Guastella, A. J., & Hickie, I. B. (2016). Oxytocin Treatment, Circuitry, and Autism: A 
Critical Review of the Literature Placing Oxytocin Into the Autism Context. Biological 
Psychiatry, 79(3), 234–242. https://doi.org/10.1016/j.biopsych.2015.06.028 
Hediger, M. L., England, L. J., Molloy, C. A., Yu, K. F., Manning-Courtney, P., & Mills, J. 
L. (2008). Reduced Bone Cortical Thickness in Boys with Autism or Autism Spectrum 
Disorder. Journal of Autism and Developmental Disorders, 38(5), 848–856. 
https://doi.org/10.1007/s10803-007-0453-6 
Holingue, C., Newill, C., Lee, L.-C., Pasricha, P. J., & Fallin, M. D. (2018). Gastrointestinal 
symptoms in autism spectrum disorder: A review of the literature on ascertainment and 
prevalence. Autism Research, 11(1), 24–36. https://doi.org/10.1002/aur.1854 
Hsiao, E. Y., McBride, S. W., Hsien, S., Sharon, G., Hyde, E. R., McCue, T., … Mazmanian, 
S. K. (2013). Microbiota Modulate Behavioral and Physiological Abnormalities Associated 
with Neurodevelopmental Disorders. Cell, 155(7), 1451–1463. 
https://doi.org/10.1016/j.cell.2013.11.024 
Jones, C., Barrera, I., Brothers, S., Ring, R., & Wahlestedt, C. (2017). Oxytocin and social 
functioning. Dialogues in clinical neuroscience, 19(2), 193–201. 
Kang, D.-W., Adams, J. B., Gregory, A. C., Borody, T., Chittick, L., Fasano, A., … 
Krajmalnik-Brown, R. (2017). Microbiota Transfer Therapy alters gut ecosystem and 
improves gastrointestinal and autism symptoms: an open-label study. Microbiome, 5(1), 10. 
https://doi.org/10.1186/s40168-016-0225-7 
Kemper KJ, Vohra S, Walls R; American Academy of Pediatrics; Task Force on 
Complementary and Alternative Medicine; Provisional Section on Complementary, Holistic, 
and Integrative Medicine. The use of complementary and alternative medicine in pediatrics. 
Pediatrics 2008;122:1374 –1386 
Kohane IS, McMurry A, Weber G, MacFadden D, Rappaport L, et al. (2012) The Co-
Morbidity Burden of Children and Young Adults with Autism Spectrum Disorders. PLOS 
ONE 7(4): e33224. https://doi.org/10.1371/journal.pone.0033224 
Krakowiak, P., Walker, C. K., Bremer, A. A., Baker, A. S., Ozonoff, S., Hansen, R. L., & 
Hertz-Picciotto, I. (2012). Maternal Metabolic Conditions and Risk for Autism and Other 
Neurodevelopmental Disorders. Pediatrics, 129(5), e1121. 
https://doi.org/10.1542/peds.2011-2583 
Lai, M.C., Lombardo, M. V., & Baron-Cohen, S. (2014). Autism. The Lancet, 383(9920), 
896–910. https://doi.org/10.1016/S0140-6736(13)61539-1 
43 
 
Lange, K. W., Hauser, J., & Reissmann, A. (2015). Gluten-free and casein-free diets in the 
therapy of autism: Current Opinion in Clinical Nutrition and Metabolic Care, 18(6), 572–
575. https://doi.org/10.1097/MCO.0000000000000228 
Li, Q., Han, Y., Dy, A. B. C., & Hagerman, R. J. (2017). The Gut Microbiota and Autism 
Spectrum Disorders. Frontiers in Cellular Neuroscience, 11. 
https://doi.org/10.3389/fncel.2017.00120 
Malkova, N. V., Yu, C. Z., Hsiao, E. Y., Moore, M. J., & Patterson, P. H. (2012). Maternal 
immune activation yields offspring displaying mouse versions of the three core symptoms of 
autism. Brain, Behavior, and Immunity, 26(4), 607–616. 
https://doi.org/10.1016/j.bbi.2012.01.011 
Mangiola, F., Ianiro, G., Franceschi, F., Fagiuoli, S., Gasbarrini, G., & Gasbarrini, A. (2016). 
Gut microbiota in autism and mood disorders. World Journal of Gastroenterology, 22(1), 
361–368. https://doi.org/10.3748/wjg.v22.i1.361 
Mišić, B., Doesburg, S. M., Fatima, Z., Vidal, J., Vakorin, V. A., Taylor, M. J., & McIntosh, 
A. R. (2015). Coordinated Information Generation and Mental Flexibility: Large-Scale 
Network Disruption in Children with Autism. Cerebral Cortex, 25(9), 2815–2827. 
https://doi.org/10.1093/cercor/bhu082 
Nair, A., Treiber, J. M., Shukla, D. K., Shih, P., & Müller, R.-A. (2013). Impaired 
thalamocortical connectivity in autism spectrum disorder: a study of functional and 
anatomical connectivity. Brain, 136(6), 1942–1955. https://doi.org/10.1093/brain/awt079 
National Center for Complementary and Integrative Health. (2011). Complementary, 
Alternative, or Integrative Health: What’s In a Name? 
https://nccih.nih.gov/health/integrative-health 
Parker, K. J., Oztan, O., Libove, R. A., Sumiyoshi, R. D., Jackson, L. P., Karhson, D. S., … 
Hardan, A. Y. (2017). Intranasal oxytocin treatment for social deficits and biomarkers of 
response in children with autism. Proceedings of the National Academy of Sciences, 114(30), 
8119–8124. https://doi.org/10.1073/pnas.1705521114 
Peñagarikano, O., Lázaro, M. T., Lu, X.-H., Gordon, A., Dong, H., Lam, H. A., … 
Geschwind, D. H. (2015). Exogenous and evoked oxytocin restores social behavior in the 
Cntnap2 mouse model of autism. Science Translational Medicine, 7(271), 271ra8. 
https://doi.org/10.1126/scitranslmed.3010257 
Rodriguez, J. I., & Kern, J. K. (2011). Evidence of microglial activation in autism and its 
possible role in brain underconnectivity. Neuron Glia Biology, 7(2–4), 205–213. 
https://doi.org/10.1017/S1740925X12000142 
44 
 
Rosenfeld, C. S. (2015). Microbiome Disturbances and Autism Spectrum Disorders. Drug 
Metabolism and Disposition, 43(10), 1557. https://doi.org/10.1124/dmd.115.063826 
Scahill, L., Aman, M. G., Lecavalier, L., Halladay, A. K., Bishop, S. L., Bodfish, J. W., … 
Dawson, G. (2015). Measuring repetitive behaviors as a treatment endpoint in youth with 
autism spectrum disorder. Autism, 19(1), 38–52. https://doi.org/10.1177/1362361313510069 
Sharon, G., Sampson, T. R., Geschwind, D. H., & Mazmanian, S. K. (2016). The Central 
Nervous System and the Gut Microbiome. Cell, 167(4), 915–932. 
https://doi.org/10.1016/j.cell.2016.10.027 
Sgritta, M., Dooling, S. W., Buffington, S. A., Momin, E. N., Francis, M. B., Britton, R. A., 
& Costa-Mattioli, M. (2019). Mechanisms Underlying Microbial-Mediated Changes in 
Social Behavior in Mouse Models of Autism Spectrum Disorder. Neuron, 101(2), 246-
259.e6. https://doi.org/10.1016/j.neuron.2018.11.018 
Teng, B. L., Nikolova, V. D., Riddick, N. V., Agster, K. L., Crowley, J. J., Baker, L. K., … 
Moy, S. S. (2016). Reversal of social deficits by subchronic oxytocin in two autism mouse 
models. Neuropharmacology, 105, 61–71. https://doi.org/10.1016/j.neuropharm.2015.12.025 
Tomova, A., Husarova, V., Lakatosova, S., Bakos, J., Vlkova, B., Babinska, K., & 
Ostatnikova, D. (2015). Gastrointestinal microbiota in children with autism in Slovakia. 
Physiology & Behavior, 138, 179–187. https://doi.org/10.1016/j.physbeh.2014.10.033 
Tyszka, J. M., Adolphs, R., Paul, L. K., & Kennedy, D. P. (2013). Largely Typical Patterns 
of Resting-State Functional Connectivity in High-Functioning Adults with Autism. Cerebral 
Cortex, 24(7), 1894–1905. https://doi.org/10.1093/cercor/bht040 
Wagner, S., & Harony-Nicolas, H. (2018). Oxytocin and Animal Models for Autism 
Spectrum Disorder. In R. Hurlemann & V. Grinevich (Eds.), Behavioral Pharmacology of 
Neuropeptides: Oxytocin (pp. 213–237). https://doi.org/10.1007/7854_2017_15 
Whiteley, P. (2017). Food and the gut: relevance to some of the autisms. Proceedings of the 
Nutrition Society, 76(4), 478–483. https://doi.org/10.1017/S0029665117002798 
Vuong, H. E., & Hsiao, E. Y. (2017). Emerging Roles for the Gut Microbiome in Autism 
Spectrum Disorder. Biological Psychiatry, 81(5), 411–423. 
https://doi.org/10.1016/j.biopsych.2016.08.024 
Yang, X.-L., Liang, S., Zou, M.-Y., Sun, C.-H., Han, P.-P., Jiang, X.-T., … Wu, L.-J. (2018). 
Are gastrointestinal and sleep problems associated with behavioral symptoms of autism 
spectrum disorder? Psychiatry Research, 259, 229–235. 
https://doi.org/10.1016/j.psychres.2017.10.040 
45 
 
Yamasue, H., & Domes, G. (2018). Oxytocin and Autism Spectrum Disorders. In R. 
Hurlemann & V. Grinevich (Eds.), Behavioral Pharmacology of Neuropeptides: Oxytocin 
(pp. 449–465). https://doi.org/10.1007/7854_2017_24 
Young, L. J., & Barrett, C. E. (2015). Can oxytocin treat autism? Science, 347(6224), 825–
826. https://doi.org/10.1126/science.aaa8120 
Zielinski, B. A., Prigge, M. B. D., Travers, B. G., Alexander, A. L., Lainhart, J. E., Lange, 
N., … Fletcher, P. T. (2014). Longitudinal changes in cortical thickness in autism and typical 
development. Brain, 137(6), 1799–1812. https://doi.org/10.1093/brain/awu083 
